Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Active, enrolledPhase 2Results postedLast updated 29 January 2026
What this trial tests
Phase 2 trial testing ACALABRUTINIB in Refractory Aggressive B-cell Lymphomas in 28 participants. Participants enrolled and being followed up; not accepting new ones.
18 and older, any sex, with Refractory Aggressive B-cell Lymphomas or Refractory B-Cell Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Complete Response Rate (CRR)Primary· 1 year 8 months
The CRR is defined as the percentage of subjects achieving an objective response of complete response (CR) according to the Lugano Classification (Chesson et al., 2014), prior to start of another non-study anticancer therapy. CR is defined as a complete metabolic and radiologic response (Lugano score 1-3, target nodes/nodal masses must regress to ≤ 1.5 cm in longest diameter.)
Group
Value
95% CI
ACALABRUTINIB and LISOCABTAGENE MARALEUCEL
22
Adverse events — posted to ClinicalTrials.gov
Time frame: All adverse events are reported from the start of acalabrutinib until 30 days after the last dose of study drug or at documented disease progression, whichever is longer. For patients without disease progression at 90 days after the last dose of study drug, only adverse events at least possibly related to study drug are reported through year 2 or disease progression, whichever occurs first (adverse events followed up to 24 months in a single patient as of November 2025.).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
ACALABRUTINIB and LISOCABTAGENE MARALEUCEL
Serious: 7/27 (26%)
Deaths: 0/27
Serious adverse events (8 terms)
Reaction
System
ACALABRUTINIB and LISOCABT…
Fever
General disorders
—
Alanine aminotransferase increased
Investigations
—
Aspartate aminotransferase increased
Investigations
—
Cytokine Release Syndrome
Investigations
—
Hypercalcemia
Metabolism and nutrition disorders
—
Hypotension
Vascular disorders
—
Nausea
Gastrointestinal disorders
—
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
—
Other adverse events (190 terms — click to expand)
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Patrick C. Johnson, MD
Last refreshed: 29 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05583149.